

Supplementary Table 4. Baseline clinical, angiographic, and procedural characteristics and in-hospital medications of patients with or without LD in both the C-P and the P-C groups

Characteristics	The C-P (n = 867)			The P-C (n = 532)		
	No LD (n = 669)	LD (n = 198)	<i>p</i> value	No LD (n = 428)	LD (n=104)	<i>p</i> value
Age, yr	61.19 ± 0.47	59.57 ± 0.76	0.071	64.65 ± 0.60	62.36 ± 1.26	0.095
Age ≥ 75 years	95 (14.2)	20 (10.1)	0.153	109 (25.5)	19 (18.3)	0.159
Male gender	537 (80.3)	166 (83.8)	0.302	305 (71.3)	78 (75.0)	0.468
Hypertension	338 (50.5)	96 (48.5)	0.628	200 (46.7)	46 (44.2)	0.663
Diabetes	179 (26.8)	43 (21.7)	0.165	104 (24.3)	34 (32.7)	0.082
Dyslipidemia	76 (11.4)	20 (10.1)	0.700	31 (7.2)	14 (13.5)	0.049
Current smoker	291 (43.5)	101 (51.0)	0.074	157 (36.7)	46 (44.2)	0.177
Family history of coronary artery disease	36 (5.4)	13 (6.6)	0.489	28 (6.5)	5 (4.8)	0.653
Previous history of angina	61 (9.1)	17 (8.6)	0.888	36 (8.4)	5 (4.8)	0.304
Previous history of heart failure	16 (2.4)	1 (0.5)	0.093	5 (1.2)	3 (2.9)	0.197
Previous history of MI	76 (11.4)	19 (9.6)	0.520	27 (6.3)	6 (5.8)	1.000
Previous history of CVA	26 (3.9)	14 (7.1)	0.080	19 (4.4)	6 (5.8)	0.605
Killip class			0.448			0.008
I	555 (83.0)	169 (85.4)		355 (85.5)	77 (74.0)	
II–IV	114 (17.0)	29 (14.6)		62 (14.5)	27 (26.0)	
Final diagnosis			1.000			0.049
Non-ST segment elevation MI	354 (52.9)	105 (53.0)		188 (43.9)	57 (54.8)	
ST segment elevation MI	315 (47.1)	93 (47.0)		240 (56.1)	47 (45.2)	
LV ejection fraction, %	52.26 ± 0.42	53.07 ± 0.72	0.356	51.56 ± 0.51	51.83 ± 1.17	0.836
Creatinine clearance, mL/min	85.56 ± 1.51	90.70 ± 2.32	0.064	76.96 ± 1.67	87.40 ± 4.59	0.034
Vascular access			0.686			0.063
Transradial approach	333 (49.8)	102 (51.5)		223 (52.1)	43 (41.3)	
Transfemoral approach	336 (50.2)	96 (48.5)		205 (47.9)	61 (58.7)	
Infarct-related artery			0.398			0.608
Left anterior descending	319 (47.7)	91 (46.0)		208 (48.6)	46 (44.2)	
Left circumflex	98 (14.6)	37 (18.7)		66 (15.4)	15 (14.4)	
Right coronary	233 (34.8)	62 (31.3)		148 (34.6)	40 (38.5)	
Left main	19 (2.8)	8 (4.0)		6 (1.4)	3 (2.9)	
Involved vessel number			1.000			0.028
Single vessel	326 (48.7)	97 (49.0)		243 (56.8)	46 (44.2)	
Left main or multi-vessel disease	343 (51.3)	101 (51.0)		185 (43.2)	58 (55.8)	
ACC/AHA lesion classification			0.073			0.486
Type A/B1	83 (12.4)	15 (7.6)		50 (11.7)	9 (8.7)	
Type B2/C	586 (87.6)	183 (92.4)		378 (88.3)	95 (91.3)	
Procedure for target lesion			0.470			0.081
Only balloon angioplasty	32 (4.8)	10 (5.1)		28 (6.5)	2 (1.9)	
Bare metal stent	21 (3.1)	3 (1.5)		10 (2.3)	5 (4.8)	
Drug-eluting stent	616 (92.1)	185 (93.4)		390 (91.1)	97 (93.3)	

Supplementary Table 4. Continued

Characteristics	The C-P (n = 867)			The P-C (n = 532)		
	No LD (n = 669)	LD (n = 198)	<i>p</i> value	No LD (n = 428)	LD (n=104)	<i>p</i> value
Use of glycoprotein IIb/IIIa inhibitor	120 (17.9)	37 (18.7)	0.834	62 (14.5)	19 (18.3)	0.361
In-hospital medications						
Aspirin	666 (99.6)	198 (100.0)	0.345	428 (100.0)	104 (100.0)	-
Clopidogrel	669 (100.0)	198 (100.0)	-	428 (100.0)	104 (100.0)	-
Ticagrelor	365 (54.6)	138 (69.7)	< 0.001	327 (76.4)	64 (61.5)	0.003
Prasugrel	304 (45.4)	60 (30.3)	< 0.001	101 (23.6)	40 (38.5)	0.003
Cilostazol	13 (1.9)	4 (2.0)	0.945	22 (5.1)	3 (2.9)	0.330
Beta-blocker	581 (86.8)	169 (85.4)	0.636	333 (77.8)	84 (80.8)	0.596
Calcium channel blockers	31 (4.6)	16 (8.1)	0.073	27 (6.3)	3 (2.9)	0.175
ACEi or ARB	540 (80.7)	166 (83.8)	0.350	314 (73.4)	87 (83.7)	0.031
Statin	635 (94.9)	189 (95.5)	0.854	400 (93.5)	99 (95.2)	0.653
Oral anticoagulants	6 (0.9)	2 (1.0)	0.884	30 (7.0)	8 (7.7)	0.832

Values are presented as mean ± standard error of mean or number (%).

LD, loading dosage; C-P, from clopidogrel to potent P2Y12 receptor inhibitor (RI); P-C, from potent P2Y12RI to clopidogrel; MI, myocardial infarction; CVA, cerebrovascular accident; LV, left ventricular; ACC, American College of Cardiology; AHA, American Heart Association; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker.